Research
Hormonal
Obesity is a major contributor to primary hypertension through mechanisms such as neurohormonal activation, inflammation, and kidney dysfunction.
Addressing obesity is crucial for managing hypertension risk.
StrongSupportsmedium confidence
Obesity accounts for much of the risk for primary hypertension through several mechanisms, including neurohormonal activation, inflammation, and kidney dysfunction.
Why this rating
The claim is based on a comprehensive review by the American Heart Association.
Source
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association
Michael E. Hall et al. · Hypertension · 2021
DOI 10.1161/hyp.0000000000000202
reviewCited 233×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →